drugset
Drugs / A2B694
last change May 2026 re-read 3 minutes ago

A2B694

Cell therapy targets MSLN

Developed for
colon carcinoma · colorectal adenocarcinoma · malignant mesothelioma · malignant pancreatic neoplasm · non-small cell squamous lung carcinoma · ovarian cancer · rectal cancer
Investigated by
A2 Biotherapeutics Inc. · Tempus AI

Trials 1

today NCT06051695 · Ph 1/2
2025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06051695 Apr 2024 → Jun 2028 expected colon carcinoma, colorectal adenocarcinoma, malignant mesothelioma, malignant pancreatic neoplasm +3 A2 Biotherapeutics Inc. Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 3

DateIssuerRelease
2026-05-21 A2 Biotherapeutics Inc. Results A2 Biotherapeutics Presents Safety and Efficacy Data from the EVEREST-2 Clinical Study, Including Update on the First Complete Response to CAR T-Cell Therapy in a Patient with Non-Small Cell Lung Cancer a2bio.com ↗
We are encouraged by the EVEREST-2 study data being presented during ASCO 2026, including updated results for the first reported complete response to CAR T-cell therapy in a patient with a hard-to-treat case of non-small cell lung cancer.
2025-11-07 A2 Biotherapeutics Inc. Results A2 Biotherapeutics Presents Initial Safety and Efficacy Data from Ongoing Phase 1/2 EVEREST-2 Study, Including First Report of a Complete Response to CAR T-Cell Therapy in a Patient with NSCLC a2bio.com ↗
The findings from EVEREST-2 include the first reported complete response (CR) in a patient with non-small cell lung cancer (NSCLC) following treatment with a CAR T-cell therapy.
2025-09-08 A2 Biotherapeutics Inc. Results A2 Biotherapeutics Presents Data from Ongoing Phase 1/2 EVEREST-2 Study During the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer a2bio.com ↗

All press releases naming this drug 3 releases

DateIssuerRelease

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as A2B694 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06051695 ↗
Modality Cell therapy “Autologous logic-gated Tmod CAR T cells” NCT06051695 ↗
Route Intravenous “single dose of A2B694 intravenously on day 0” NCT06051695 ↗
Target MSLN “Tmod CAR T-cell therapy will enable the killing of tumor target cells (those cells that express MSLN” NCT06051695 ↗